MiNK Therapeutics (NASDAQ:INKT) Releases Earnings Results, Beats Estimates By $0.21 EPS

MiNK Therapeutics (NASDAQ:INKT) released its quarterly earnings results on Friday. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21, Zacks reports.

MiNK Therapeutics Trading Down 3.6%

INKT traded down $0.47 during midday trading on Friday, reaching $12.75. The company’s stock had a trading volume of 19,480 shares, compared to its average volume of 20,730. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00. The stock has a market cap of $58.65 million, a P/E ratio of -4.43 and a beta of 0.33. The company has a fifty day simple moving average of $14.33 and a 200 day simple moving average of $12.81.

Analyst Upgrades and Downgrades

INKT has been the subject of a number of analyst reports. HC Wainwright raised shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Friday, August 15th. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. B. Riley raised shares of MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Wall Street Zen downgraded shares of MiNK Therapeutics to a “strong sell” rating in a research report on Saturday, August 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.